These three names dominate metabolic-research discussion, and they're constantly confused. Here's a clear, research-only comparison of how Retatrutide, Tirzepatide and Semaglutide differ at the receptor level — no hype, no claims.
- The core difference is receptor coverage: Semaglutide is single (GLP-1), Tirzepatide is dual (GIP+GLP-1), Retatrutide is triple (GIP+GLP-1+Glucagon).
- Retatrutide (LY-3437943) is the newest and least-studied of the three.
- All three are reference compounds for in-vitro research only.
The one-line difference
It comes down to how many receptors each one engages. Retatrutide is a triple agonist, Tirzepatide is a dual agonist, and Semaglutide is a single GLP-1 agonist. More targets does not mean ‘better’ — it means a different research profile.
Side-by-side
The table below summarises how the three compare in the published research literature.
Where Retatrutide fits
As the newest triple agonist, Retatrutide (LY-3437943) is the most-discussed but least mature in the literature. For background, see our full Retatrutide research guide.
Sourcing reference material in India
Whichever you're researching, the rule is the same: insist on HPLC ≥99% purity and a batch COA. See how to buy research peptides in India safely.
| Property | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon (triple) | GIP + GLP-1 (dual) | GLP-1 (single) |
| Class | Triple agonist | Dual agonist | GLP-1 agonist |
| Code name | LY-3437943 | LY-3298176 | — |
| Research stage | Investigational (newest) | Established in literature | Most-studied |
Retatrutide (LY-3437943)
The triple-agonist research peptide, HPLC ≥99% with a batch COA. Pan-India COD.
Frequently asked questions
What is the difference between Retatrutide, Tirzepatide and Semaglutide?
They differ by receptor coverage: Semaglutide targets GLP-1 only, Tirzepatide targets GIP and GLP-1, and Retatrutide targets GIP, GLP-1 and glucagon (a triple agonist).
Which is the newest?
Retatrutide (LY-3437943) is the newest and least-studied of the three in the research literature.
Are these available in India for research?
Retatrutide is stocked at OMNIPOTENT as an HPLC ≥99% reference compound with a COA. All are supplied for in-vitro research only.
Does a triple agonist mean it's better?
No. More receptor targets simply means a different research profile, not a superior one. This is a research distinction, not a recommendation.